iFANN
    Last updated
    Argenx
    Biotechnology

    Argenx

    Belgium flagBelgium

    "Advancing immunology to improve lives."

    Founded 2008 Amsterdam, Netherlands and Boston, Massachusetts CEO: Karen Massey
    Community

    About

    Argenx SE is a global biotechnology company founded in 2008 in Ghent, Belgium. The company focuses on developing antibody-based therapies for patients suffering from severe autoimmune diseases and cancer. Argenx leverages proprietary technology platforms to create innovative treatments, with a particular emphasis on orphan drugs that address unmet medical needs.

    The company's most prominent product is VYVGART (efgartigimod alfa), which has received approvals for treating generalized myasthenia gravis and primary immune thrombocytopenia. Argenx also has a pipeline of other potential therapies, including empasiprubart and ARGX-119, and actively collaborates with academic researchers through its Immunology Innovation Program.

    Products & Sub-brands

    VYVGART (efgartigimod alfa)empasiprubartARGX-119

    Frequently Asked Questions

    Where is Argenx headquartered?
    Argenx has a global presence with operational headquarters in Boston, Massachusetts, and its corporate headquarters are listed in Amsterdam, Netherlands, with its founding in Ghent, Belgium.
    What are Argenx's main products?
    Argenx's primary product is VYVGART (efgartigimod alfa), used to treat generalized myasthenia gravis and primary immune thrombocytopenia, with other pipeline products in development.
    Who founded Argenx?
    Argenx was founded in 2008 by Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier, who aimed to develop advanced antibody therapies for autoimmune diseases and cancer.
    How much revenue does Argenx generate?
    Argenx generated $4.25 billion in annual revenue (TTM) and $2.2 billion in full-year 2024 product sales, with significant year-over-year growth.
    Who are Argenx's main competitors?
    Argenx competes in the biotechnology sector with companies such as Genmab A/S, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, AbbVie Inc., and Amgen Inc.

    Keywords

    biotechnologypharmaceuticalsimmunologyautoimmune diseasescancer therapyantibody therapiesorphan drugsVYVGARTefgartigimod alfa

    Sources

    LeadiqGlobalDataBusiness Model Canvas TemplatePitchgradeForbesArgenx Annual Report

    Company Info

    Founded
    2008
    Founder
    Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier
    CEO
    Karen Massey
    Headquarters
    Amsterdam, Netherlands and Boston, Massachusetts
    Industry
    Biotechnology
    Revenue
    $4.25 billion (TTM)
    Global Net Product Sales (Q3 2024)
    $573 million
    Global Net Product Sales (Q4 2024)
    $737 million
    Full-Year 2024 Sales
    $2.2 billion
    Annual Revenue (TTM)
    $4.25 billion
    Year-over-Year Revenue Growth
    74.6%
    Net Profit Margin
    30.4%
    Primary Therapy Focus
    Severe autoimmune diseases and cancer
    Key Technology Platforms
    SIMPLE Antibody Platform, NHANCE, ABDEG, POTELLIGENT

    Official Website

    www.argenx.com/

    Links

    Join the community

    fans discussing